By the Top Tier Newswire AI Desk · November 17, 2026 at 9:41 AM ET · reviewed against 3 wire stories
IMMUNITYBIO INC (IBRX) is up +5.85% in the latest session. Our newswire has captured 3 stories on IBRX across 2 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
ImmunityBio (IBRX) shares rose 5.85% to $6.33, driven by the CEO’s announcement of fresh clinical data for Anktiva following a successful bladder cancer trial. The company stated that an FDA filing is expected within weeks.
What Happened
ImmunityBio plans to present full response rates at an upcoming medical meeting to demonstrate the benefit added by Anktiva. The company recently reported Q3 2026 financial results and regulatory milestones. Additionally, ImmunityBio and Rafa Laboratories received Israeli Ministry of Health approval for ANKTIVA Plus BCG, and the company announced the first patients in Europe treated with ANKTIVA.
Institutional interest in the stock has increased recently. BlackRock and Vanguard Capital Management added shares of IBRX, along with SLS and IOVA, to their Q3 buy lists. The two firms acquired a combined 8.12 million shares across those three tickers.
What The Data Shows
The stock printed five fresh 52-week highs on November 17, 2026. Despite a 25.3% decline over the previous eight sessions, the current price of $6.33 sits within the 52-week range of $1.95 to $12.43. The company has a market capitalization of $6.4 billion and remains unprofitable with a trailing twelve-month EPS of $1.08. Revenue grew 121.2% over the trailing twelve months.
Intraday trading showed the stock opening at $6.00 and reaching a session high of $6.38 at 9:35 AM ET. Volume stood at 1.3 million shares, which is 0.1 times the three-month daily average. Insider activity over the last 90 days included two sales totaling $1.1 million, with no buys recorded. Congressional disclosures show two buys by Lisa McClain in late September, each valued between $1,001 and $15,000.
What To Watch
Investors will monitor the timing of the FDA filing for Anktiva and the presentation of full response rates at the scheduled medical meeting.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
IBRX · Nov 17 session (5-min) · +5.22% vs prior close · updated 8:46 PM ETAI sentiment, last 36h · averaged over 3 stories · 63/100 bullish
The headlines behind the move
Story flow · 3 stories on the wire, last 36h · hover or tap a dot for the headline
3d agoStocktwits NewsBULLISH 74Product/PR
IBRX CEO Reveals Fresh Anktiva Data After Bladder Cancer Trial Win — Says FDA Filing Is Just Weeks Away
ImmunityBio plans to present the full response rates at a medical meeting, showing how much benefit Anktiva added.
4d agoSeeking AlphaNEUTRAL 52Product/PR
ImmunityBio, Inc. (IBRX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript
ImmunityBio, Inc. (IBRX) UBS Global Biopharma Conference 2026 November 16, 2026 5:40 AM ESTCompany ParticipantsRichard Adcock - President, CEO &...
4d agoStocktwits NewsBULLISH 63General
SLS, IBRX And IOVA Join Merck And Lilly On BlackRock’s Q3 Buy List — A Vanguard Unit Adds All Of Them Too
BlackRock and Vanguard Capital Management added all five stocks in Q3, including 8.12 million shares across SLS, IBRX and IOVA.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →